rivaroxaban
Selected indexed studies
- Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. (Clin Pharmacokinet, 2014) [PMID:23999929]
- Rivaroxaban and the EINSTEIN clinical trial programme. (Blood Coagul Fibrinolysis, 2019) [PMID:30920394]
- Rivaroxaban for the treatment of venous thromboembolism in pediatric patients. (Expert Rev Cardiovasc Ther, 2020) [PMID:32935597]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. (2014) pubmed
- Rivaroxaban and the EINSTEIN clinical trial programme. (2019) pubmed
- Rivaroxaban for the treatment of venous thromboembolism in pediatric patients. (2020) pubmed
- Rivaroxaban for prevention and treatment of venous thromboembolism. (2019) pubmed
- Rivaroxaban for treatment of livedoid vasculopathy: A systematic review. (2021) pubmed
- Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD. (2020) pubmed
- Rivaroxaban to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease: a narrative review. (2025) pubmed
- Venous Thromboembolism in Children: The Rivaroxaban Experience. (2024) pubmed
- Role of rivaroxaban in the prevention of atherosclerotic events. (2019) pubmed
- Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. (2022) pubmed